China-United States Research Collaborations in Antimicrobial Resistance
A strong synergy can result from China-US antimicrobial resistance (AMR) collaborations given similarities and differences between their respective healthcare systems and research infrastructures. The Antibacterial Resistance Leadership Group has employed a model of realistic growth, starting with a feasible, relatively low-resource observational study in a critical priority pathogen. This and other observational studies will provide vital scientific information required for the rational design of future interventional trials. In addition, it provides a mutual, low-risk opportunity for determining the strengths and opportunities of the research collaboration. Issues identified during the observational studies can be addressed prior to the initiation of high-resource interventional studies. Collaborative clinical AMR studies between China and the United States have tremendous potential to decrease AMR rates, improve responsible antibiotic use, and ultimately improve the lives of patients in both countries.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 67(2018), suppl_2 vom: 13. Nov., Seite S142-S145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Duin, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 07.11.2019 Date Revised 03.01.2020 published: Print ErratumIn: Clin Infect Dis. 2019 Mar 19;68(7):1254 Pfaff, Melanie [corrected to Paff, Melanie]. - PMID 30776073 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciy694 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290554187 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290554187 | ||
| 003 | DE-627 | ||
| 005 | 20231225065005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciy694 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM290554187 | ||
| 035 | |a (NLM)30423056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Duin, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a China-United States Research Collaborations in Antimicrobial Resistance |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.11.2019 | ||
| 500 | |a Date Revised 03.01.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Clin Infect Dis. 2019 Mar 19;68(7):1254 Pfaff, Melanie [corrected to Paff, Melanie]. - PMID 30776073 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A strong synergy can result from China-US antimicrobial resistance (AMR) collaborations given similarities and differences between their respective healthcare systems and research infrastructures. The Antibacterial Resistance Leadership Group has employed a model of realistic growth, starting with a feasible, relatively low-resource observational study in a critical priority pathogen. This and other observational studies will provide vital scientific information required for the rational design of future interventional trials. In addition, it provides a mutual, low-risk opportunity for determining the strengths and opportunities of the research collaboration. Issues identified during the observational studies can be addressed prior to the initiation of high-resource interventional studies. Collaborative clinical AMR studies between China and the United States have tremendous potential to decrease AMR rates, improve responsible antibiotic use, and ultimately improve the lives of patients in both countries | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Gu, Peidi |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Paff, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Rebekka M |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Beth |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yunsong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lanjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fujie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhengyin |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Vance G |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Minggui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 67(2018), suppl_2 vom: 13. Nov., Seite S142-S145 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2018 |g number:suppl_2 |g day:13 |g month:11 |g pages:S142-S145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciy694 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2018 |e suppl_2 |b 13 |c 11 |h S142-S145 | ||